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Epidermal growth factor receptor tyrosine kinase inhib-
itor (EGFR TKI) monotherapy has been regarded as the
standard ﬁrst-line treatment of advanced non–small cell
lung cancer (NSCLC) in patients with sensitive epidermal
growth factor receptor gene (EGFR) mutations. Acquired
resistance is inevitable, however, which presents a
challenge in the management of patients with such mu-
tations. Here, we summarize the clinical evidence on
treatment strategies for both EGFR TKI–naive and ac-
quired EGFR TKI–resistant NSCLC. We reviewed the
published literature and abstracts of oral and poster
presentations from international conferences addressing
treatment strategies that are in use or in clinical devel-
opment to improve the survival of patients who are
EGFR TKI naive and EGFR TKI resistant. Various strate-
gies have been explored to manage EGFR TKI resistance
with the aim of prolonging the survival of patients with
EGFR-mutant NSCLC. Combination strategies in the ﬁrst-
line treatment have been studied most to improve the
beneﬁt from EGFR TKI monotherapy and delay the
occurrence of resistance. After failure of EGFR TKI
monotherapy, continuation of EGFR TKI therapy com-
bined with chemotherapy, immunotherapy, or targeted
agents has been used to overcome the development of
resistance. In addition, novel compounds designed to act
on speciﬁc targets associated with EGFR TKI resistance
have been in continued clinical development. Treatment
regimens that are superior to EGFR TKI monotherapy in
the ﬁrst-line or to overcome acquired EGFR TKI resis-
tance in patients with NSCLC and EGFR mutations still
need to be developed. Results of ongoing studies will
provide more insight into effective treatment strategies
for patients with EGFR mutations.
 2015 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.Journal of Thoracic Oncology Vol. 11 No. 2: 174-186Keywords: Non–small cell lung cancer; Epidermal growth
factor receptor tyrosine kinase inhibitor; Acquired resis-
tance; Combination strategy
Introduction
Lung cancer is the most common cancer and re-
mains the leading cause of cancer-related death in men
and women worldwide. Approximately 80% to 85% of
lung cancers are non–small cell lung cancer (NSCLC).
More than half of patients in whom NSCLC has been
newly diagnosed have advanced-stage disease at diag-
nosis, which confers a poor prognosis. Despite ad-
vances in chemotherapy, median overall survival (OS)
is less than 12 months1 and the 5-year survival rate is
less than 1%.2
Epidermal growth factor receptor (EGFR), a tyrosine
kinase receptor, is one of the landmark targets of NSCLC
therapy. Several large clinical studies3–8 have demon-
strated that epidermal growth factor receptor tyrosine
kinase inhibitors (EGFR TKIs) are superior to chemo-
therapy as ﬁrst-line treatments, showing improved
Table 1. Phase III Studies of EGFR TKI Monotherapy as First-Line Treatment of Patients with NSCLC and EGFR Mutations
Study Treatment No. Patients
Median PFS
(mo)
Median OS
(mo) RR (%)
IPASS3 Geﬁtinib vs. carboplatin-paclitaxel 132 vs. 129 9.5 vs. 6.3a,9 21.6 vs. 21.99 71.2 vs. 47.3a
WJTOG34054 Geﬁtinib vs. cisplatin-docetaxel 86 vs. 86 9.2 vs. 6.3a 36 vs. 399 62.1 vs. 32.2a
NEJ0025 Geﬁtinib vs. carboplatin-paclitaxel 114 vs. 114 10.8 vs. 5.4a 27.7 vs. 26.69 73.7 vs. 30.7a
OPTIMAL6
(CTONG-0802)
Erlotinib vs. gemcitabine-carboplatin 82 vs. 72 13.1 vs. 4.6a 22.7 vs. 28.99 83 vs. 36a
First-Signal7 Geﬁtinib vs. gemcitabine-cisplatin 26 vs. 16 8.0 vs. 6.3a 27.2 vs. 25.6 84.6 vs. 37.5a
EURTAC8 Erlotinib vs. cisplatin-docetaxel/gemcitabine 86 vs. 87 9.7 vs. 5.2a 19.3 vs. 19.5 58 vs. 15
LUX-Lung 3b,10 Afatinib vs. cisplatin-pemetrexed 230 vs. 115 11.1 vs. 6.9a 31.6 vs. 28.211 56 vs. 23a
LUX-Lung 6c,12 Afatinib vs. gemcitabine-cisplatin 242 vs. 122 11.0 vs. 5.6a 23.6 vs. 23.511 66.9 vs. 23a
ap < 0.005.
bPFS and RR results are from an independent review assessment. The results of the investigator review assessment were as follows: PFS ¼
11.1 vs. 6.7 mo (p ¼ 0.001) and RR ¼ 69% vs. 44% (p ¼ 0.001).
cPFS and RR results are from an independent review assessment. The results of the investigator review assessment were as follows: PFS ¼
13.7 vs. 5.6 mo (p < 0.0001) and RR ¼ 74.4% vs. 31.1% (p < 0.0001).
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non–small cell lung cancer; PFS, progression-free survival; OS,
overall survival; RR, response rate; IPASS, Iressa Pan-Asia Study; WJTOG, West Japan Thoracic Oncology Group; NEJ002, North East Japan
002; First-Signal, First-Line Single-Agent Iressa versus Gemcitabine and Cisplatin Trial in Never-Smokers with Adenocarcinoma of the Lung;
EURTAC, European Randomised Trial of Tarceva versus Chemotherapy; OPTIMAL, Erlotinib versus chemotherapy as ﬁrst-line treatment for
patients with advanced EGFR mutation-positive NSCLC: a multicenter, open-label, randomized, phase 3 study; LUX-Lung 3, Phase III study of
afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations; LUX-Lung 6, Afatinib versus
cisplatin plus gemcitabine for ﬁrst-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations.
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for patients with advanced-stage NSCLC and sensitizing
EGFR mutations. Therefore, EGFR TKIs have been widely
recognized as the preferred initial therapy for patients
with activating EGFR mutations. Acquired EGFR TKI
resistance eventually developed in most such patients
and progressed within 12 months, however. Importantly,
not all patients with EGFR mutations are similarly sen-
sitive to EGFR TKIs.
In this review, we provide an overview of viable
treatment strategies for patients with NSCLC and EGFR
mutations. We also summarize clinical studies of sys-
tematic therapy aimed at improving the survival beneﬁt
in both EGFR TKI–naive patients and in those with
acquired-resistance.
Methods
We searched PubMed, MEDLINE, and clinicaltrials.
gov to identify clinical studies that included treatment
of patients with NSCLC and EGFR mutations. We also
searched for relevant abstracts of oral and poster pre-
sentations submitted to American Society of Clinical
Oncology and European Society for Medical Oncology
from 2010 to 2015. The search strategy included medi-
cal subject headings or keywords for the concepts EGFR
TKI naïveté or EGFR TKI resistance combined with
medical subject headings or keywords for NSCLC and
EGFR mutations. Articles or abstracts published in a
language other than English were excluded.EGFR TKI–Naive Patients
EGFR TKI Monotherapy
The ﬁrst generation of EGFR TKIs—geﬁtinib, erloti-
nib, and icotinib—were designed to reversibly combine
with the adenosine triphosphate binding sites and thus
block EGFR-induced activation of downstream signaling,
and they have been extensively investigated in NSCLC.
Six randomized controlled phase III trials3–8 (Table 1)
have demonstrated that the ﬁrst-generation EGFR TKIs
signiﬁcantly improved the response rate (RR) and PFS
compared with chemotherapy as ﬁrst-line treatment of
advanced NSCLC harboring EGFR mutations. However,
OS was not improved, possibly because of treatment
crossover at progression. A meta-analysis13 of the six
phase III trials conﬁrmed the efﬁcacy of EGFR TKI
therapy as ﬁrst-line treatment in patients with NSCLC
and EGFR mutations. When compared with chemo-
therapy, EGFR TKIs were found to result in signiﬁcantly
better PFS and RR, but not OS.
In contrast to ﬁrst-generation EGFR TKIs, the
second-generation EGFR TKIs such as afatinib or
dacomitinib are irreversible inhibitors with greater af-
ﬁnity for the EGFR kinase domain, and they also inhibit
other members of the EGFR family (human epidermal
growth factor receptors 2, 3, and 4).14 Afatinib was
approved as a ﬁrst-line treatment in patients with
NSCLC and sensitizing EGFR mutations after demon-
strating favorable results in the LUX-Lung 3 and LUX-
Lung 6 trials (see Table 1).10,12 Overall survival was
176 Zhou and Yao Journal of Thoracic Oncology Vol. 11 No. 2still not improved in either trial.11 A meta-analysis15
that included second-generation EGFR TKI trials
conﬁrmed that in patients with EGFR mutations, EGFR
TKI therapy delayed disease progression compared
with chemotherapy.
Whether different EGFR TKIs have different efﬁcacy or
toxicity proﬁles in patients with NSCLC and
EGFR mutations remains uncertain. A recent meta-anal-
ysis16 indicated that erlotinib, geﬁtinib, afatinib, and ico-
tinib had equivalent efﬁcacy but different toxicity proﬁles
for patients with NSCLC and EGFR mutations. Two pro-
spective head-to-head trials that may address this ques-
tion are currently ongoing: LUX-Lung 7 (NCT01466660, a
randomized phase IIb trial comparing geﬁtinib with afa-
tinib) and ARCHER 1050 (NCT01774721, a phase III trial
comparing geﬁtinib with dacomitinib).
Molecular Patterns to Predict Response to
EGFR TKIs
We already know that patients harboring exon 19 de-
letions (del19) and L858R substitution in exon 21 usually
beneﬁt more from EGFR TKIs than do patients with wild-
type mutations.15 These two patterns account for
approximately 90% of all EGFR-activating mutations17
and are regarded as EGFR TKI–sensitizing mutations.
However, relatively little is knownabout other uncommon
EGFR mutations such as insertion mutations in exon 20,
whichmay be associatedwith a lack of response to TKIs.17
Recently, several reports indicated that the efﬁcacy of
EGFR TKIs may differ for del19 and exon 21 L858R
mutations. A meta-analysis18 incorporating all available
data from correlative studies conﬁrmed that patients
with the del19 mutation were associated with statisti-
cally longer PFS than were those with exon 21 L858R
EGFR mutations. Additionally, superior PFS was found in
patients with the EGFR del19–positive genotype who
received different EGFR-targeted agents (geﬁtinib, erlo-
tinib, or afatinib). Analysis of two phase III trials, LUX-
Lung 3 and LUX-Lung 6, indicated that afatinib
improved OS for patients with EGFR del19 mutations,
but not for patients with L858R mutations. These results
indicate that patients with EGFR del19 and L858R mu-
tations may have differential responses to EGFR TKIs.11
Several hypotheses have been proposed to explain the
higher efﬁcacy of EGFR TKIs in patients with NSCLC and
exon 19 deletions than in those with L858R mutations;
for example, exon 19 deletions might be more efﬁciently
inhibited by EGFR TKIs than are exon 21 L858R muta-
tions, T790M mutations occur more frequently in exon
21 L858R mutations, or exon 21 L858R mutations
coexisting with other uncommon mutations might affect
the sensitivity of exon 21 L858R mutations to EGFR
TKIs. Nevertheless, the true mechanism remains un-
clear.18–20In addition to EGFR mutation patterns, several other
biomarkers have been suggested for identifying patients
who are likely to achieve limited responses with EGFR
TKIs. One is the gatekeeper T790M point mutation, which
increases the afﬁnity of EGFR for adenosine triphosphate
and consequently attenuates the binding efﬁcacy of EGFR
TKIs.21 The de novo T790Mmutation has been associated
with shorter duration of the response to EGFR TKIs and
was a negative predictive marker for PFS in patients with
NSCLC who were treated with ﬁrst-line EGFR TKI.22,23
Another predictive biomarker is BIM (a proapoptotic B-
cell CLL/lymphoma 2 [BCL-2] family protein), which is
pivotal in apoptosis induction by EGFR TKIs in EGFR-
mutant NSCLC. In the European Randomized Trial of
Tarceva versus Chemotherapy (EURTAC), PFS with erlo-
tinib was signiﬁcantly longer for those patients with high
levels of BIM expression than for those with low or in-
termediate levels (12.9 versus 7.2 months, respectively;
p ¼ 0.0003).24
The lack of sufﬁcient data has impeded determination
of the optimal therapeutic strategy for patients with EGFR
mutations, such as insertion mutations in exon 20, who
are initially insensitive to EGFR TKIs. Although personal-
ized therapy may be required to enhance survival, further
investigations are needed to develop effective strategies.
Combinations of EGFR TKIs and Chemotherapy
Single-agent EGFR TKI is considered a standard ﬁrst-
line therapy for patients with activating EGFR mutations.
To further increase survival beneﬁt, combining chemo-
therapy or targeted drugs with EGFR TKIs has been
widely explored. In general, there are three approaches
to combination of EGFR TKIs with chemotherapy.
Concurrent Combinations. Before the predictive effect
of EGFRmutations was validated, four randomized Phase
III clinical trials of concurrent combinations of EGFR
TKIs and chemotherapy were conducted in unselected
populations.25–28 However, all four trials failed to show a
better outcome of the combination than with standard
chemotherapy. But whether the combination would
improve outcomes in patients with activating EGFR
mutations was not known. The Cancer and Leukemia
Group B 30406 study29 investigated the combination of
paclitaxel/carboplatin and erlotinib versus erlotinib
alone in a population enriched for the EGFRmutation. No
signiﬁcant differences between treatment groups from
the standpoints of PFS, OS, and RR were reported. The
efﬁcacy in each treatment arm was greater for patients
with EGFR mutations than for those without the EGFR
mutations (Table 2). Because of its small sample size,
however, this study lacked sufﬁcient statistical power to
determine the efﬁcacy of erlotinib with paclitaxel/car-
boplatin in patients with EGFR mutations.
Table 2. Studies of Combination of EGFR TKIs with Other Agents in Patients with NSCLC and EGFR Mutations
Study Phase Treatment
Combination
Pattern
No.
Patients
Median PFS
(months)
Median OS
(months) RR (%)
In EGFR TKI–naive patients
CALGB 3040629 II Erlotinib vs. erlotinib-carboplatin-paclitaxel Concurrent 33 vs. 33 14.1 vs. 17.2 31.3 vs. 38.1 70 vs. 73
NEJ00530 II Geﬁtinib-carboplatin/pemetrexed Concurrent vs. sequentially
alternating
41 vs. 39 18.3 vs. 15.3 41.9 vs. 30.7a,b 87.8 vs. 84.6
Cheng Y, et al. 201531 II Geﬁtinib-pemetrexed vs. geﬁtinib Concurrent 126 vs. 65 15.8 vs. 10.9a NRb 80.2 vs. 73.8
FASTACT-232 III Gemcitabine-cisplatin/carboplatin-erlotinib
vs. gemcitabine-cisplatin/carboplatin-placebo
Intercalated 49 vs. 48 16.8 vs. 6.9a 31.4 vs. 20.6a 84 vs. 15a
SATURN33 III Erlotinib vs. placebo Maintenance 307 vs. 311 12.3 weeks vs.
11.1 weeksa
12 vs. 11a NA
INFORM34,35 III Geﬁtinib vs. placebo Maintenance 15 vs. 15 16.6 vs. 2.8a 46.9 vs. 21.0a NA
JO 2556736 II Erlotinib-bevacizumab vs. erlotinib Concurrent 77 vs. 77 16.0 vs. 9.7a b 69 vs. 64
Ichihara E, et al. 201537 II Geﬁtinib-bevacizumab Concurrent 42 14.4 (18.0 vs. 9.4a,c) NRb 73.8
In patients with acquired EGFR TKI resistance
IMPRESS38 III Geﬁtinib-cisplatin/pemetrexed vs.
placebo-cisplatin/pemetrexed
Concurrent 133 vs. 132 5.4 vs. 5.4 14.8 vs. 17.2b 31.6 vs. 34.1
LUX-Lung 539 III Afatinib-paclitaxel vs. chemotherapy Concurrent 134 vs. 68 5.6 vs. 2.8a 12.2 vs. 12.2 32.1 vs. 13.2a
Janjigian YY, et al. 201140 I/II Erlotinib-cetuximab Concurrent 19 3.0 NRb 0
Janjigian YY, et al. 201441 Ib Afatinib-cetuximab Concurrent 126 4.7 (4.8 vs. 4.6d) NA 29 (32 vs. 25d)
ap  0.05.
bImmature overall survival data/immature at the time of publishing.
cData in patients with exon 19 deletions versus with exon 21 L858R mutations.
dData in T790M-positive versus T790M-negative patients.
EGFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non–small cell lung cancer; PFS, progression-free survival; OS, overall survival; RR, response rate; NR, not
reached; NA, not available/not assessed.
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178 Zhou and Yao Journal of Thoracic Oncology Vol. 11 No. 2A phase II study, NEJ005/TCOG0902,30 compared the
concurrent combination of platinum-based chemo-
therapy and geﬁtinib with sequentially alternating geﬁ-
tinib and platinum-based chemotherapy in chemo-naive
patients with NSCLC and EGFR mutations. Both regimens
showed promising efﬁcacy. The median OS for the con-
current regimen was 41.9 months, which was signiﬁ-
cantly better than that observed in the sequential
alternating regimen group (p ¼ 0.042) (see Table 2).
Another recently reported phase II study comparing
geﬁtinib and pemetrexed with geﬁtinib alone in East
Asian patients with nonsquamous NSCLC and EGFR mu-
tations demonstrated that the combination approach led
to a signiﬁcant improvement of nearly 5 months in PFS
compared with geﬁtinib monotherapy (see Table 2).31
Results of an ongoing phase III study, NEJ009,42 evalu-
ating geﬁtinib in combination with carboplatin plus
pemetrexed versus geﬁtinib alone will provide further
insight on concurrent chemotherapy in combination with
EGFR TKIs as ﬁrst-line treatment of patients with EGFR
mutations. (Please note that pemetrexed has not been
approved in combination with geﬁtinib and carboplatin.)
Intercalated Combinations. A potential antagonistic ef-
fect of an EGFR TKI plus chemotherapy concurrent com-
bination exists because EGFR TKI induces G1-phase cell
cycle arrest that protects cancer cells from the lethal effect
of cell cycle phase–dependent chemotherapy, which ar-
rests cells at the mitotic cell cycle phase. In contrast, the
intercalated administration of EGFR TKI and chemo-
therapy has been postulated as a plausible option because
it provides temporal separation of these two classes of
drugs with conﬂicting pharmacodynamics.43
Intercalated combinations of chemotherapy and
EGFR TKIs were explored in two FASTACT randomized
trials in unselected patients with advanced NSCLC.32,44
Signiﬁcantly improved PFS was reported with interca-
lated combination in the phase II FASTACT-1 study.44 In
the phase III FASTACT-2 study,32 patients were
randomly assigned to gemcitabine-platinum and inter-
calated erlotinib for six cycles, followed by erlotinib until
progression or to platinum-gemcitabine and placebo for
six cycles, followed by erlotinib at progression. The
intercalated arm showed signiﬁcant improvements in
PFS and OS,32 with no differences in toxicity compared
with in the chemotherapy plus placebo arm. As expected,
signiﬁcant improvements in PFS and OS were noted only
in patients with activating EGFR mutations (see Table 2);
however, whether the beneﬁt was due to a synergistic
effect of intercalated combination of EGFR TKI and
chemotherapy or due to maintenance treatment remains
unclear. Moreover, the study did not address whether
the intercalated combination is more effective than EGFR
TKI monotherapy in patients with EGFR mutations.Sequential Combinations with EGFR TKIs as Main-
tenance Therapy. In clinical practice, EGFR mutations
are often detected after chemotherapy has already been
initiated, a situation for which no consensus recom-
mendation exists. An acceptable approach would be to
complete four to six cycles of chemotherapy and then
switch to EGFR TKIs as maintenance in patients who did
not have progression while receiving chemotherapy. In
clinical trials of EGFR TKIs as maintenance therapy
following ﬁrst-line cytotoxic chemotherapy, patients
with EGFR mutations had longer PFS than did those
receiving placebo,33,34 thus suggesting that the use of
EGFR TKIs as maintenance therapy is a plausible option
(see Table 2).
Most published studies exploring the combination
strategy of EGFR TKI plus chemotherapy have involved a
population of nonselected patients with NSCLC and
have not focused on patients with EGFR mutations. At
the time these studies were designed, EGFR mutation
was not known to be a predictive biomarker. Therefore,
the unmet need is to test this combination in patients
with activating EGFR mutations. Its favorable results
compared with those of EGFR TKI alone have already
been observed in phase II studies, and ongoing large-
scale prospective studies will further validate its
effectiveness.
Combinations of EGFR TKIs and Other Targeted
Agents
The development of targeted agents such as bev-
acizumab and cetuximab, which were designed to act
speciﬁcally either on receptors or ligands that have
important roles in tumor biology, has provided new
opportunities for treatment of patients with advanced
NSCLC. To improve the treatment outcome for patients
with EGFR mutations, biologically synergistic combina-
tions with EGFR TKIs were extensively explored as
various ﬁrst-line treatment regimens.
Bevacizumab, a recombinant humanized monoclonal
antibody, binds to vascular endothelial growth factor A
(VEGF-A), causing inhibition of tumor-induced angio-
genesis. A phase II study showed that erlotinib and
bevacizumab signiﬁcantly improved PFS compared
with erlotinib alone, with an improvement of almost 6
months in patients with NSCLC and EGFR mutations
(see Table 2). Notably, toxicity led to the discontinuation
of bevacizumab in 41% of patients.36 Another re-
cently published single-arm phase II study of geﬁtinib
plus bevacizumab indicated that median PFS differed
signiﬁcantly between patients with EGFR del19 and
L858R point mutations (see Table 2).37 Further investi-
gation of this combination regimen is warranted to
validate its efﬁcacy and substantial toxicity. In addition
to bevacizumab, ramucirumab, another antiangiogenesis
Figure 1. Mechanisms of acquired resistance to EGFR TKIs and agents managing the resistance.
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thelial growth factor receptor 2, is undergoing a phase III
clinical trial in combination with erlotinib to evaluate its
efﬁcacy and safety in patients with EGFR mutations
(NCT02411448).
Cetuximab, an EGFR monoclonal antibody, binds to
the extracellular domain of EGFR and prevents ligand-
dependent receptor activation. A preclinical study
suggested a synergistic effect of geﬁtinib and cetux-
imab, thus supporting combined EGFR targeting as a
clinically exploitable strategy.45 An ongoing phase II–III
study of cetuximab in combination with afatinib versus
afatinib alone in treatment-naive patients with EGFR
mutations will examine whether afatinib plus cetux-
imab is better than afatinib alone (SWOG-S1403;
NCT02438722).
Patients with Acquired EGFR TKI
Resistance
Acquired resistance denotes disease progression after
an initial response. Acquired resistance to EGFR TKIs
inevitably develops in most patients who experienced sig-
niﬁcant tumor regressions when treated with the drug.
Identiﬁcation of a T790M mutation in a patient with ac-
quired resistance to geﬁtinib20 led to further research
aimed at understanding the resistance mechanisms.
Several potential mechanisms of resistance to EGFR inhi-
bition have been identiﬁed (Fig. 1): (1) development ofsecondary EGFRmutations such as the gatekeeper T790M
point mutation, which is the most frequently occurring
mechanism of resistance46; (2) activation of downstream
signaling pathways, likely on account of acquired muta-
tions such asmutations inBRAF or PIK3CA47; (3) activation
of parallel signaling pathways, including mesenchymal-
epithelial transition factor (MET), human epidermal re-
ceptor 2 (HER2), ﬁbroblast growth factor receptor, and
AXL, to bypass the inhibited EGFR protein48–51; and (4)
histologic transformation, speciﬁcally epithelial-to-
mesenchymal transition or small cell transformation.52
Clonal heterogeneity also contributes to resistance to
EGFR TKIs. Cancer cells evolve by stepwise somatic muta-
tions with sequential subclonal selection (Fig. 2). It is likely
that increased resistance to multiple drugs will eventually
develop in clones. Tumors in such a state might be rescued
by drug combinations.53 Unfortunately, most studies of
investigational drugs ordrug combinations in patientswith
acquired resistance to ﬁrst-generation EGFR TKI therapy
have reported little to no efﬁcacy.Management According to Progression Patterns
Disease progression in patients receiving EGFR TKI
treatment can be generally divided into two patterns:
oligo-progression and systemic progression.
In oligo-progression, the primary tumor is controlled
and the patient experiences slow, asymptomatic metas-
tasis at a few (usually ﬁve or fewer) intracranial or
Figure 2. Evolution of cancer cells’ clonal heterogeneity in response to drug treatment.
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such as stereotactic ablative radiotherapy can be adop-
ted for disease management. Combination of TKIs with
local ablation is likely to control the disease, thus
resulting in survival beneﬁt.54–56 For patients with sys-
temic progression, systemic treatment is considered the
best choice. In the following sections, we present
completed and ongoing efforts to overcome resistance
and an algorithm of treatment strategies for patients
with systemic progression after an initial response to
EGFR TKIs.
Switch to Chemotherapy
Because no successful or reliable therapeutic strate-
gies to overcome EGFR TKI resistance are currently
available, switching to chemotherapy remains the most
widely accepted approach, with support from current
practice guidelines.57 Because of the complex nature of
EGFR TKI resistance, the sensitivity of subsequent
chemotherapy may be affected. Two retrospective
studies were conducted in an effort to validate this hy-
pothesis but showed inconsistent results.58,59 A recently
reported retrospective cohort study found that peme-
trexed single-agent therapy provided signiﬁcantly longer
PFS than did platinum-based doublet chemotherapy for
patients with NSCLC and EGFR mutations who failed
ﬁrst-line therapy with EGFR TKIs.60 Prospective ran-
domized studies are needed to provide a deﬁnitive
recommendation regarding the therapeutic strategy of
chemotherapy for this population.
Continuation of EGFR TKIs
Discontinuation of TKIs might lead to rapid disease
progression.61 It is plausible to continue treatment with
an EGFR TKI beyond disease progression. In practice,disease management usually depends on clinical factors
such as symptoms and tumor burden. Some asymp-
tomatic patients with progression continue to obtain
clinical beneﬁt from EGFR TKI treatment and can delay
switching to chemotherapy.62 In addition to continuing
treatment with initially effective EGFR TKIs, combina-
tions with chemotherapy or other targeted agents have
been explored or are under investigation.
Continuation of Single-Agent EGFR TKI Beyond Pro-
gression. The single-arm phase II study ASPIRATION63
showed that continuation of erlotinib beyond disease
progression is a feasible treatment option. The difference
between the time-to-response evaluation criteria in solid
tumors progression or death and the time to off-erlotinib
progression if erlotinib was extended beyond the
response evaluation criteria in solid tumors progression
was 3.7 months in those patients whose disease pro-
gressed after erlotinib. However, randomized studies are
needed to further validate the effect of continuation of
EGFR TKIs and identify the optimal subsets of patients
with EGFR mutations who can beneﬁt from post-
progression treatment with EGFR TKI.63
Continuation of EGFR TKIs and Chemotherapy. Given
the potential heterogeneity of EGFR TKI resistance in
cancer cells, it is assumed that continuation of EGFR TKI
therapy acts on cells remaining sensitive to this agent,
whereas chemotherapy acts on the cells resistant to the
EGFR TKI.64
The phase III IMPRESS study38 compared continued
geﬁtinib in combination with cisplatin and pemetrexed
with cisplatin and pemetrexed in patients with EGFR
mutations. Unfortunately, the combination including
geﬁtinib failed to prolong PFS and had a deleterious
February 2016 Improving Outcomes with EGFR-Mutant NSCLC 181effect on OS compared with that of chemotherapy alone
(see Table 2). Considering the complicated mechanism of
resistance to TKI, the study results indicate that
personalized treatment is required to overcome such
resistance, and future studies should be considered to
identify the subsets of patients who could beneﬁt from
this combination strategy.
A phase III trial (LUX-Lung 5) compared afatinib and
paclitaxel to the investigator’s choice of chemotherapy
alone in patients who progressed while receiving erlo-
tinib/geﬁtinib and afatinib. The combination regimen
signiﬁcantly improved PFS and RR compared with
chemotherapy alone; OS was similar in both arms (see
Table 2).39
Several ongoing prospective studies may provide
a deﬁnitive recommendation about the combination
of chemotherapy and erlotinib (NCT01928160,
NCT02064491, and NCT02098954) in patients with
EGFR TKI–acquired resistance.
Continuation of EGFR TKIs and Other Targeted
Agents. The prospect of targeting two different path-
ways simultaneously, possibly leading to disease control
in patients with EGFR TKI resistance, is appealing.
Cetuximab has been used predominantly in combi-
nation with EGFR TKIs against drug-resistant tumors.
Encouraging preclinical data showed that the combina-
tion of cetuximab with afatinib induced tumor regres-
sion in erlotinib resistant tumors by decreasing the
phosphorylation of total EGFR resulting in inhibition of
its signaling.65 On the basis of these data, a phase Ib
study evaluated the combination of afatinib and cetux-
imab in 126 patients with NSCLC who had progressed
during treatment with erlotinib/geﬁtinib. The combina-
tion demonstrated an overall response rate (ORR) of
29% and PFS of 4.7 months. Patients with T790M-
positive and T790M-negative mutations had a similar
PFS (see Table 2).41 Whether this dual EGFR blockade
strategy is generally efﬁcacious with any EGFR TKI in
combination with cetuximab should be clariﬁed in
future studies. In a phase I–II study of erlotinib plus
cetuximab in patients with resistance to erlotinib, no
responses were seen.40
EGFR TKI Rechallenge After a Drug Holiday
Another strategy to regain sensitivity to EGFR TKI
is to rechallenge with the same or a different TKI after
progression of disease in patients receiving a TKI
initially and undergoing subsequent chemotherapy. A
possible explanation for the clinical beneﬁt of an
EGFR TKI rechallenge is that some cytotoxic agents
have been reported to restore the sensitivity of
NSCLC cells to EGFR TKIs by increasing EGFR phos-
phorylation.66 It is also possible that chemotherapyduring the EGFR TKI–free interval, which is equiva-
lent to a drug holiday for TKI, could decrease the
number of EGFR TKI–resistant tumor cells. In a
single-arm prospective phase II trial, 23 patients who
had previously been controlled (showed response or
disease stabilization) with initial geﬁtinib treatment
for at least 3 months and progressed while under-
going subsequent chemotherapy were recruited.
Partial response and disease control rate were ob-
served in 21.7% and 65.2% of the patients who were
retreated with geﬁtinib, respectively.67 Another phase
II study evaluating the clinical effects of geﬁtinib
rechallenge in patients with EGFR mutations is
ongoing (NVALT16, NCT02025218).
Second- and Third-Generation EGFR TKIs
Although afatinib is the most promising second-
generation EGFR TKI and has proven to be successful
in the ﬁrst-line setting, its activity against acquired
resistance in two phase II studies (LUX-Lung 1 and LUX-
Lung 4) was modest.68,69 Other second-generation TKIs,
such as dacomitinib and neratinib, have also been tested
against acquired resistance, but limited efﬁcacy has been
observed.70,71
Third-generation EGFR TKIs speciﬁcally designed to
overcome T790M mutation are currently being devel-
oped. Although only phase I clinical study results have
been presented, the activity of the third-generation EGFR
TKIs against the T790M mutation has been demon-
strated to be impressively promising. The ORR for AZD-
9291 (80 mg daily) was 66% with a PFS of 10.9 months
in patients with T790M mutations.72 CO-1686 (500 mg
twice daily) showed an ORR of 60% and 57% in heavily
pretreated patients harboring the T790M mutation in
tissue and plasma testing, respectively.73 Similarly,
HM61713 resulted in a 54.8% ORR with a 95.2% disease
control rate in patients with T790M mutations.74 The
safety proﬁle of these third-generation TKIs differs from
that of ﬁrst- or second-generation TKIs and is associated
with less frequent and less severe gastrointestinal and
skin toxicity. One possible explanation is that these
agents are highly selective with less effect on normal
cells with wild-type EGFR mutations than on ﬁrst- or
second-generation TKIs. The promising efﬁcacy and mild
toxicity of AZD-9291 and CO-1686 will be validated in
large prospective studies: AURA3 (NCT02151981) and
TIGER3 (NCT02322281), respectively.
In treatment-naive patients with NSCLC and EGFR
mutations, AZD-9291 also showed encouraging results
from a recently reported phase I study (ORR 70%, 6-
month PFS rate 87%).75 Phase III studies of AZD-
9291 (FLAURA, NCT02296125) and CO-1686 (TIGER
1, NCT02186301) in treatment-naive patients with
NSCLC and EGFR mutations are ongoing for head-to-
Table 3. Part of Ongoing Studies of Targeted Agents Developed to Overcome EGFR TKI Resistance
Targeted Agent Treatment Arms Phase
ClinicalTrials.gov
Identiﬁer
cMET inhibitors
Tivantinib (ARQ197) Tivantinib þ erlotinib II NCT01580735
Cabozantinib (XL184) Cabozantinib þ erlotinib II NCT01866410
Cabozantinib (XL184) Cabozantinib II NCT02132598
Volitinib (AZD6094) Volitinib þ geﬁtinib I NCT02374645
INC280 INC280 þ EGF816 I and II NCT02335944
INC280 INC280 þ geﬁtinib II NCT01610336
PI3K/AKT/mTOR inhibitors
NVP-BKM120 BKM120 þ geﬁtinib I NCT01570296
NVP-BKM120 BKM120 þ erlotinib II NCT01487265
MK-2206 MK2206 þ geﬁtinib I NCT01147211
MK-2206 MK2206 þ erlotinib II NCT01294306
MAPK inhibitors
Selumetinib (AZD6244) Selumetinib þ vandetanib I NCT01586624
Selumetinib (AZD6244) AZD9291 þ selumetinib vs. AZD9291 þ
AZD6094 (volitinib) vs. AZD9291 þ MEDI4736
I NCT02143466
Selumetinib (AZD6244) Selumetinib þ geﬁtinib I and II NCT02025114
Selumetinib (AZD6244) Erlotinib vs. erlotinib þ MK-2206 vs.
selumetinib þ MK-2206 vs. sorafenib
II NCT01248247
HSP90 inhibitors
NVP-AUY922 (VER52296) AUY922 vs. pemetrexed/docetaxel II NCT01646125
NVP-AUY922 (VER52296) AUY922 II NCT01854034
SNX-5422 SNX-5422 I NCT01851096
Ganetespib (STA9090) Ganetespib þ ziv-aﬂibercept I NCT02192541
AKT, Ak murine thymoma viral oncogene; MET, mesenchymal epithelial transition factor; PI3K, phosphatidylinositide 3-kinases; mTOR,
mammalian target of rapamycin; MAPK, mitogen-activated protein kinase; HSP90, heat shock protein 90.
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standpoints of efﬁcacy and tolerability.76,77 Additional
data obtained in the future will help determine the
optimal strategy for using third-generation EGFR TKIs
in patients with NSCLC and EGFR mutations: whether to
use them as ﬁrst-line therapy or after failure of ﬁrst-
generation TKIs.Treatment Strategies Targeting Alternate
Pathways
The third-generation EGFR TKIs speciﬁcally target-
ing the T790M mutation elicited responses in early
clinical studies, but most of the other agents targeting
alternate pathways contributing to TKI resistance
produced modest clinical beneﬁt. For example, MET
ampliﬁcation is the second most common mechanism
of acquired resistance to EGFR TKIs after T790M point
mutation, and targeting MET to overcome resistance is
a viable option from biologic standpoint. In a phase II
clinical study, the MET inhibitor cabozantinib admin-
istered in combination with erlotinib to patients who
had EGFR mutations and progressed with an EGFR TKI
resulted in an ORR of 8.1% and PFS of 3.7 months, thus
warranting further clinical investigation.78 Treatment
with another MET inhibitor, INC280, in combinationwith geﬁtinib in patients with EGFR-mutated and MET-
positive NSCLC resulted in an ORR of 17%.79 Another
newly emerged agent is heat shock protein 90 (HSP90)
inhibitor. The HSP90 is a molecular chaperone that is
responsible for the conformational maturation and
stabilization of its substrate proteins, including EGFR.
AUY922, an HSP90 inhibitor showed single-agent
clinical activity in patients with NSCLC and EGFR mu-
tations who had progressed just after EGFR TKI ther-
apy with a median PFS rate of 45% at 18 weeks.80
However, a phase II study of AUY922 and erlotinib in
patients with EGFR-mutant lung cancer with acquired
resistance did not meet its primary end point (ORR
16%).81 Other compounds targeting alternate path-
ways, such as HER2/HER3 inhibitors, phosphoinositide
3-kinase/Ak murine thymoma viral oncogene/
mammalian target of rapamycin (PI3K/AKT/mTOR)
inhibitors, and mitogen-activated protein kinase in-
hibitors, are in various stages of clinical development
(Table 3). More encouraging results from these trials
are expected in the near future.
Immunotherapy
Another potential strategy is the use of immune
checkpoint inhibitors such as programmed death
(PD)-1 pathway inhibitors, which have drawn much
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strated that mutant EGFR signaling drives expression
of programmed death-ligand 1 (PD-L1) and that
blockade of the PD-1 receptor improved survival of
mice with EGFR-mutant tumors.82 Preliminary results
of a study investigating the combination of nivolumab
(anti-PD-1 monoclonal antibody) and erlotinib re-
ported an ORR of 19% (four of 21 patients, with three
of four responders having previously progressed
while receiving erlotinib).83 Nivolumab has been
recently approved by the FDA for the treatment of
patients with squamous NSCLC after failure of
chemotherapy. Further investigations of nivolumab as
monotherapy or in combination with EGFR TKI in
patients with NSCLC and EGFR mutations will provide
further insight into the role of immunotherapy
(NCT02323126).
Conclusions and Future Perspectives
EGFR TKI monotherapy has been regarded as the
standard ﬁrst-line therapy for patients with NSCLC and
EGFR-sensitive mutations. To maximize the survival
beneﬁt from ﬁrst-line treatment in patients with NSCLC
and EGFR mutations and delay the occurrence of
resistance, EGFR TKI-based combination therapy is a
reasonable strategy that has been explored using
various approaches. The combination of EGFR TKI with
chemotherapy or the antiangiogenesis monoclonal
antibody has achieved encouraging efﬁcacy, which is to
be validated in future large-scale studies. Despite the
success of EGFR TKIs as front-line treatment, resistance
to these drugs is inevitable and creates a signiﬁcant
challenge in the management of patients with EGFR
mutations. The heterogeneity of tumors and the
complicated mechanisms involved in EGFR TKI resis-
tance have impeded the development of successful so-
lutions for overcoming this resistance. One possible
solution is a combination strategy, including combina-
tions of EGFR inhibitors with chemotherapy, immuno-
therapy, or various targeted agents. Few conclusive
studies with encouraging results have been reported to
date, thus indicating the need for further inves-
tigations—especially of EGFR TKIs in combination with
chemotherapy. To obtain meaningful results, careful
selection of patients and design of randomized clinical
trials should be considered. Novel compounds desig-
ned to act on a speciﬁc target associated with EGFR
TKI resistance have been under continued clinical
development. In this regard, the third-generation EGFR
TKIs designed to speciﬁcally target T790M mutations
may lead to a dramatic change in the treatment para-
digm for patients with EGFR mutations within the next
few years. As more data become available in the future,
we can expect the development of novel drugs withdemonstrated efﬁciency in overcoming resistance to
EGFR TKIs.
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